Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Return on Capital Employed (2023 - 2026)

Compass Therapeutics' Return on Capital Employed history spans 4 years, with the latest figure at 37.2% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 1389.0% to 37.2% in Q1 2026 year-over-year; TTM through Mar 2026 was 37.2%, a 1389.0% increase, with the full-year FY2025 number at 43.87%, down 336.0% from a year prior.
  • Return on Capital Employed hit 37.2% in Q1 2026 for Compass Therapeutics, down from 34.45% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CMPX hit a ceiling of 32.36% in Q4 2023 and a floor of 61.56% in Q2 2025.
  • Historically, Return on Capital Employed has averaged 41.15% across 4 years, with a median of 37.34% in 2024.
  • Biggest five-year swings in Return on Capital Employed: crashed -2452bps in 2025 and later surged 1389bps in 2026.
  • Tracing CMPX's Return on Capital Employed over 4 years: stood at 32.36% in 2023, then dropped by -29bps to 41.67% in 2024, then grew by 17bps to 34.45% in 2025, then dropped by -8bps to 37.2% in 2026.
  • Business Quant data shows Return on Capital Employed for CMPX at 37.2% in Q1 2026, 34.45% in Q4 2025, and 44.21% in Q3 2025.